The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Primary mediastinal B-cell lymphoma is a distinct subtype of diffuse large-B-cell lymphoma that is closely related to nodular sclerosing Hodgkin's lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. METHODS: We conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-cell lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. RESULTS: The patients had a median age of 30 years (range, 19 to 52) and a median tumor diameter of 11 cm; 59% were women. During a median of 5 years of follow-up, the event-free survival rate was 93%, and the overall survival rate was 97%. Among the 16 patients who were involved in the retrospective analysis at another center, over a median of 3 years of follow-up, the event-free survival rate was 100%, and no patients received radiotherapy. No late morbidity or cardiac toxic effects were found in any patients. After follow-up ranging from 10 months to 14 years, all but 2 of the 51 patients (4%) who received DA-EPOCH-R alone were in complete remission. The 2 remaining patients received radiotherapy and were disease-free at follow-up. CONCLUSIONS: Therapy with DA-EPOCH-R obviated the need for radiotherapy in patients with primary mediastinal B-cell lymphoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00001337.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Self-citationReduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
Phan, R. T., & Dalla-Favera, R. (2004) · Nature · doi:10.1038/nature03147 · Cited by 679
Wilson, W. H., Dunleavy, K. M., Pittaluga, S., Hegde, U. P., Grant, N., Steinberg, S. M., Raffeld, M. A., Gutierrez, M. E., Chabner, B. A., Staudt, L. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1391 · Cited by 326
Self-citationGenomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.
Joos, S., Küpper, M., Ohl, S., von Bonin, F., Mechtersheimer, G., Bentz, M., Marynen, P., Mӧller, P., Pfreundschuh, M. G., Trümper, L. H. P., et al. (2000) · PubMed · Cited by 273
Joos, S., Menz, C. K., Wrobel, G., Siebert, R., Gesk, S., Ohl, S., Mechtersheimer, G., Trümper, L., Möller, P., Lichter, P., et al. (2002) · Blood · doi:10.1182/blood.v99.4.1381 · Cited by 238
Zinzani, P. L., Martelli, M., Magagnoli, M., Pescarmona, E., Scaramucci, L., Palombi, F., Bendandi, M., Martelli, M. P., Ascani, S., Orcioni, G. F., et al. (1999) · Blood · doi:10.1182/blood.v94.10.3289.422k32_3289_3293 · Cited by 181
Primary Mediastinal B-Cell Lymphoma
Pileri, S. A., Gaidano, G., Zinzani, P. L., Falini, B., Gaulard, P., Zucca, E., Pieri, F., Berra, E., Sabattini, E., Ascani, S., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63815-1 · Cited by 167
Wilson, W. H., Jung, S.-H., Porcu, P., Hurd, D., Johnson, J., Martin, S. E., Czuczman, M., Lai, R., Said, J., Chadburn, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.056531 · Cited by 167
Self-citationDunleavy, K. M., Hakim, F. T., Kim, H. K., Janik, J. E., Grant, N., Nakayama, T., White, T., Wright, G. W., Kwak, L. W., Gress, R. E., et al. (2005) · Blood · doi:10.1182/blood-2004-08-3198 · Cited by 136
Self-citationLate Effects in the Era of Modern Therapy for Hodgkin Lymphoma
Hodgson, D. C. (2011) · Hematology · doi:10.1182/asheducation-2011.1.323 · Cited by 110
Kirwan, M., Vulliamy, T., Marrone, A., Walne, A. J., Beswick, R., Hillmen, P., Kelly, R., Stewart, A., Bowen, D., Schonland, S. O., et al. (2009) · Human Mutation · doi:10.1002/humu.21115 · Cited by 109
Cited by
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
Marx, A., Chan, J. K. C., Coindre, J.-M., Detterbeck, F., Girard, N., Harris, N. L., Jaffe, E. S., Kurrer, M. O., Marom, E. M., Moreira, A. L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000654 · Cited by 603
Self-citationRoschewski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E. S., Staudt, L. M., Lai, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70106-3 · Cited by 463
Self-citationPD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A., Patel, S. P., & Kurzrock, R. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 461
Metadata
- Authors
- Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., Staudt, L. M., Jaffe, E. S., & Wilson, W. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-04-11
- Volume
- 368
- Issue
- 15
- Pages
- 1408-1416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001196047
- Cited by
- 569
- References
- 18
- FWCI
- 36.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.